Life Sciences

  • June 10, 2026

    Greenberg Traurig Hires 2 IP Litigators From Goodwin Procter

    Greenberg Traurig LLP announced Wednesday that it had brought on two veteran litigators from Goodwin Procter LLP to its New York office, bolstering its intellectual property litigation practice as the law evolves to keep pace with ever-changing technological innovations.

  • June 10, 2026

    Alachua Wants DOD's $147M Chapter 11 Claim Slashed To $5M

    Biotech group Alachua Government Services asked a Delaware bankruptcy judge to trim the U.S. Department of Defense's Chapter 11 claim by $142 million, saying the government relied upon inapplicable federal regulations in claims connected to rejected contracts.

  • June 10, 2026

    Abbott Offered Faulty Health Plan Option, Ex-Worker Says

    Abbott Laboratories violated federal benefits law by offering a health plan option with higher premiums and lower deductibles without disclosing that participants would always pay less if they chose a high-deductible plan, according to a proposed class action filed Wednesday in Illinois federal court.

  • June 10, 2026

    J&J Hit With $32M Verdict In LA Baby Powder Cancer Trial

    A Los Angeles jury Tuesday awarded $32 million to the family of a woman who died of mesothelioma and who said she used Johnson's Baby Powder on herself and her children for decades, finding the product was a substantial factor in causing her illness. 

  • June 10, 2026

    AmeriHealth Unit, PBM Look To Escape Pharmacy Fee Suit

    The AmeriHealth Caritas Health Plan and its in-house pharmacy benefits manager asked a federal court to toss a proposed class action over "transmission fees," alleging the law that required disclosure of those fees, Pennsylvania's Human Services Code, doesn't let private parties sue.

  • June 10, 2026

    DC Circ. Asked To Freeze DOJ's Medical Pot Rescheduling

    A trade association for drug-testing companies and a biopharma firm developing marijuana-derived drugs have urged the D.C. Circuit to hit pause on a U.S. Department of Justice rule rescheduling state-sanctioned medical pot while their challenge to the policy change plays out.

  • June 10, 2026

    Amgen Can't Amend Petition To Address Potential Double Tax

    Drugmaker Amgen isn't entitled to amend its petition to protect against possible double taxation after an eight-week trial and briefing in its income-allocation case already have been completed, the U.S. Tax Court said, noting that the trial concluded in January 2025.

  • June 10, 2026

    $25M Patent Verdict Against Ferring Backed By Del. Court

    Swiss drugmaker Ferring Pharmaceuticals Inc. on Wednesday lost its bid to dodge a $25 million verdict in a Delaware federal court patent case over an experimental enema used to treat a particularly deadly form of diarrhea.

  • June 10, 2026

    Goodwin, Covington Lead Parabilis' $670M Upsized IPO

    Venture-backed biotechnology firm Parabilis Medicines hit the public markets Wednesday after raising $670 million in its upsized initial public offering.

  • June 10, 2026

    Insurance Cos. Score Dismissal Of Zepbound Coverage Case

    A D.C. federal judge Wednesday agreed to toss a proposed class action against CVS Caremark and CareFirst BlueCross BlueShield from a worker who challenged coverage denials for Zepbound to treat sleep apnea, holding an exclusion in his employee health plan that the companies administered complied with federal benefits law.

  • June 10, 2026

    Lab To Pay $4.9M To Settle AGs' COVID Test Pricing Suit

    Eighteen states' attorneys general have entered into a $4.87 million settlement with GS Labs to resolve claims that the defunct testing company overcharged consumers for COVID-19 tests, according to statements issued Wednesday.

  • June 10, 2026

    Acadia Pharma Must Face Investors' Drug Approval Claims

    Acadia Pharmaceuticals must face investors' class action claims it misstated the likelihood that it would get regulatory approval to market its psychosis drug pimavanserin for expanded use, a California federal judge determined, finding a key question about a regulator's directions should be decided by a jury.

  • June 10, 2026

    Conn. Woman Says Pharmacy 'Grossly' Exceeded Med Dose

    A New York compounding pharmacy injured a Connecticut woman by providing her with a medication that contained a "grossly excessive" amount of the active ingredient, as much as 91,511% of the dose on the label, according to a product liability and malpractice lawsuit.

  • June 09, 2026

    Novartis, AbbVie Lose Bid To Halt Wash. 340B Pharmacy Law

    A Washington federal judge declined Tuesday to block a state law passed to protect prescription drug access for low-income and uninsured patients, rejecting arguments from AbbVie and Novartis that the new measure illegally adds to pharmaceutical manufacturers' obligations under the federal 340B Drug Pricing Program.

  • June 09, 2026

    Morrison Foerster Brings On Sidley Patent Litigation Duo

    A pair of Sidley Austin LLP patent and trade secrets litigators, including the firm's co-leader of its global intellectual property practice, have departed for Morrison Foerster LLP, according to an announcement made Tuesday.

  • June 09, 2026

    Agensys Sues Biopharmas For Alleged Trade Secret Theft

    Agensys Inc. filed a trade secret misappropriation suit in California federal court Tuesday against a U.S.-based cancer research firm and two alleged Chinese affiliates, claiming they stole confidential information for oncology antibodies developed at Agensys and that the theft was "willful and malicious."

  • June 09, 2026

    Fed. Circ. 'Recalibrates' Analysis For Constitutional Standing

    The Federal Circuit eased the line between constitutional and statutory standing last month when reviving A.L.M. Holding Co.'s infringement suit against Zydex Industries Private Ltd., in a decision attorneys say makes standing more accessible and clarifies how patent licensors can maintain their rights.

  • June 09, 2026

    4th Circ. Revives Ex-Gilead Worker's Defamation Suit

    The Fourth Circuit revived Tuesday a lawsuit from a former biopharmaceutical company employee after finding that he'd sufficiently backed his claim for vicarious liability against Gilead Sciences Inc., but refused to draw a co-worker back into the case.

  • June 09, 2026

    Eli Lilly Wins Order Halting Alleged Trulicity Fraud

    A Florida federal judge signed off Tuesday on a preliminary injunction pausing a prescription cost share program purportedly for Church of God in Christ members that pharmaceutical giant Eli Lilly and Co. says is actually a fraud scheme to resell GLP-1 drug Trulicity on the secondary market.

  • June 09, 2026

    McKesson, Rite Aid Trust Clash Over Ch. 11 Claims Transfer

    McKesson locked horns Tuesday in New Jersey bankruptcy court with a trust created by Rite Aid's first Chapter 11 plan over whether the medication supplier must hand over antitrust claims against pharmaceutical companies.

  • June 09, 2026

    BioTech Co. Hit Investor Suit Over Cancer Test Trial Miss

    Biotechnology company Grail Inc. was hit with a proposed investor class action alleging that it misled investors about the likelihood its cancer screening blood test would demonstrate effectiveness in a clinical trial, which the public learned in February was unsuccessful.

  • June 09, 2026

    Biopharma Founder's Nonsolicit Clause Void Under Calif. Law

    A biopharmaceutical company's co-founder prevailed Monday in convincing North Carolina's business court that nonsolicitation restrictions in his contract were void after they were deemed unenforceable under California law.

  • June 09, 2026

    Ex-Zydus Unit Exec Alleges 'Second-Class Citizen' Treatment

    A female executive at Zydus Pharmaceuticals' pet health unit said in New Jersey federal court that she was treated as a second-class citizen by her male counterparts, claiming she was constructively discharged due to the hostile and discriminatory conduct she faced because she is a woman.

  • June 09, 2026

    Novanta Buys Riverpoint In $1.45B Deal Steered By 3 Firms

    Medical technology provider Novanta Inc., advised by Ropes & Gray LLP and King & Spalding LLP, on Tuesday announced plans to acquire medical device maker Riverpoint Medical, led by Goodwin Procter LLP, from private equity shop Arlington Capital Partners in a deal worth up to $1.45 billion.

  • June 09, 2026

    4th Circ. Lets Hartford Unit Off The Hook For Drug Test Fight

    A Hartford unit doesn't owe coverage to a drug testing company accused of reporting false positive drug tests due to substandard quality control, the Fourth Circuit ruled Tuesday, saying the suit is related to an earlier claim that was covered by another insurer.

Expert Analysis

  • Series

    Law School's Missed Lessons: Intentional Career-Building

    Author Photo

    A successful legal career is built through intention: understanding expectations, assessing strengths honestly and proactively seeking opportunities to grow and cultivating relationships that support your development, say Erika Drous and Hillary Mann at Morrison Foerster.

  • Trending At The PTAB: The Policies That Are Redefining IPR

    Author Photo

    The evolution of the Patent Trial and Appeal Board's inter partes review institution regime last year, coupled with the policy considerations behind that evolution, marks a shift toward greater gatekeeping of the U.S. Patent and Trademark Office's resources and patent enforcement rights, say attorneys at Finnegan.

  • 4 Trends Shaping Drug And Medical Device Law For 2026

    Author Photo

    2025 saw some significant legal developments with potential impact for drug and device manufacturers, ranging from growing skepticism in science and regulatory entities to new regulation of artificial intelligence, say attorneys at Faegre Drinker.

  • Trending At The PTAB: The Journey Of IPR Institution In 2025

    Author Photo

    Over the course of 2025, inter partes review institution at the Patent Trial and Appeal Board evolved into a more restrictive, policy-driven regime with reshaped discretionary briefing and assessment, and increasing procedural requirements, say attorneys at Finnegan.

  • A Meaningful Shift In FDA's Biosimilarity Analysis

    Author Photo

    The U.S. Food and Drug Administration's potential pivot away from routinely requiring comparative efficacy studies for interchangeable biosimilar applications would not lower regulatory standards, but instead allow applicants to allocate resources toward establishing more probative evidence, says Theodore Thompson at Stinson.

  • 4 Developments That Defined The 2025 Ethics Landscape

    Author Photo

    The legal profession spent 2025 at the edge of its ethical comfort zone as courts, firms and regulators confronted how fast-moving technologies and new business models collide with long-standing professional duties, signaling that the profession is entering a period of sustained disruption that will continue into 2026, says Hilary Gerzhoy at HWG Law.

  • Navigating AI In The Legal Industry

    Author Photo

    As artificial intelligence becomes an increasingly integral part of legal practice, Law360 guest commentary this year examined evolving ethical obligations, how the plaintiffs bar is using AI to level the playing field against corporate defense teams, and the attendant risks of adoption.

  • How Fractional GCs Can Manage Risks Of Engagement

    Author Photo

    As more organizations eliminate their in-house legal departments in favor of outsourcing legal work, fractional general counsel roles offer practitioners an engaging and flexible way to practice at a high level, but they can also present legal, ethical and operational risks that must be proactively managed, say attorneys at Boies Schiller.

  • 2025 Legal Milestones That Will Shape Psychedelics Sector

    Author Photo

    As 2025 draws to a close, psychedelic drug development stands at an inflection point, experiencing unprecedented momentum through recent sweeping regulatory changes and landmark clinical milestones, amid rapidly evolving regulatory expectations, say Odette Hauke at Odette Alina LLC and Kimberly Chew at Husch Blackwell.

  • Series

    Nature Photography Makes Me A Better Lawyer

    Author Photo

    Nature photography reminds me to focus on what is in front of me and to slow down to achieve success, and, in embracing the value of viewing situations through different lenses, offers skills transferable to the practice of law, says Brian Willett at Saul Ewing.

  • What Defense Teams Must Know About PFAS Testing Methods

    Author Photo

    Whether testing for per- and polyfluoroalkyl substances produces results meaningful for litigation depends on the validity of the sampling methodology — so effectively defending these claims requires understanding the scientific and legal implications of different PFAS testing protocols, say attorneys at Hollingsworth.

  • Series

    Law School's Missed Lessons: Practical Problem Solving

    Author Photo

    Issue-spotting skills are well honed in law school, but practicing attorneys must also identify clients’ problems and true goals, and then be able to provide solutions, says Mary Kate Hogan at Quarles & Brady.

  • Intellectual Property Challenges In AI-Driven Drug Discovery

    Author Photo

    Given the adoption of artificial intelligence-based drug discovery platforms and the U.S. Patent and Trademark Office's recent guidance on determining inventorship in AI-assisted inventions, practitioners must consider unprecedented questions regarding inventorship, patentability standards and infringement liability, says Paul Calvo at Sterne Kessler.

  • Reel Justice: 'The Mastermind' And Juror Decision-Making

    Author Photo

    The recent art heist film “The Mastermind” forces viewers to discern the protagonist’s ambiguous motives and reconcile contradictions, offering lessons for attorneys about how a well-crafted trial narrative can tap into the psychological phenomena underlying juror decision-making, says Veronica Finkelstein at Wilmington University.

  • Learning From 2025 FCA Trends Targeting PE In Healthcare

    Author Photo

    False Claims Act enforcement trends and legislative developments from this year signal intensifying state and federal scrutiny of private equity's growing footprint in healthcare, and the urgency of compliance, says Lisa Re at Arnold & Porter.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.